7 research outputs found

    ATP-dependent chromatin remodelers - Analysis of expression patterns and impact on gene regulation

    Get PDF
    ATP-dependent chromatin remodelers are enzymes which use the energy from ATP hydrolysis to alter the chromatin structure. Thus, they play a key role in the transcriptional control of many important cellular processes such as proliferation,senescence and differentiation.The first part of this study focused on CHD5, a novel chromatin remodeling enzyme. To gain further insight into its expression profile and biological function, polyclonal peptide antisera were, together with a commercially available antiserum, successfully established for use in western blot, immunoprecipitation and immunofluorescence staining. ATP-dependent chromatin remodelers are expressed by very different patterns ranging from ubiquitous expression to an expression restricted to specific cell populations. So far, CHD5 expression was thought to be restricted to neural-related tissues. Here, it was shown for the first time that CHD5 expression is not restricted to neural tissues but additionally expressed in rodent testes. Furthermore, several cell lines were tested for CHD5 expression on transcript and protein level. CHD5 expression was not detected in any of the tested neuroblastoma and glioblastoma cell lines. In neuroblastoma cell lines this was expected due to the suggested function as tumor suppressor. Furthermore, a primary astrocyte culture was established. No CHD5 could be detected in protein lysates from astrocytes but was found in those from murine neural stem cells. This suggests that CHD5 expression in brain is restricted to neural stem cells and probably also to neurons. In the second part of this thesis, the impact of the chromatin remodelers CHD4 and BRG1 on a TNFα-induced inflammatory response was investigated. BRG1 and CHD4 expression was disrupted by a siRNA-mediated knockdown in HEK293 cells. After stimulations with TNFα for one to four hours, gene induction of typical inflammatory NF-ÎșB target genes was determined by RT-qPCR. BRG1 and CHD4 were both required for the efficient induction of all tested target genes exclusively after one hour but not after four hours of TNFα treatment. Expression of the housekeeping gene ß-actin was unaffected. Surprisingly, although CHD4 is mainly known to be involved in transcriptional repression, a requirement for CHD4 in active transcription during this inflammatory response was revealed. To gain further insight into the mechanism of involvement, co-immunoprecipitations of the NF-ÎșB subunit p65 with BRG1 and CHD4,respectively, were performed upon TNFα stimulation. No robust interactions between these proteins could be observed. Furthermore, ChIP experiments with the NF-ÎșB subunit p50, histone H3 and CHD4 were carried out on the model target gene CXCL2. p50 was recruited to the promoter of CXCL2 rapidly after TNFα was added. Histone H3 binding to the promoter and the open reading frame of the gene strongly decreased within the first hour of TNFα stimulation, indicating that chromatin remodeling took place during the early period of gene induction. Recruitment of CHD4 was nonconclusive. Thus, the mechanism of how BRG1 and CHD4 act during TNFα response needs to be investigated further. In summary, a major influence of the chromatin remodelers BRG1 and CHD4 on the TNFα-induced gene activation during its early phase in HEK293 cells was demonstrated

    Aspirin use and bleeding events during thrombocytopenia after autologous stem-cell transplantation for multiple myeloma

    Get PDF
    BackgroundIn patients with cardiovascular (CV) comorbidities that necessitate antiplatelet therapy (APT), its optimal management during chemotherapy-induced thrombocytopenia remains elusive, as the risk of bleeding has to be balanced against the risk of CV events. The purpose of this study was to assess the risk for bleeding with APT during thrombocytopenia in patients with multiple myeloma undergoing high-dose chemotherapy and subsequent autologous stem-cell transplantation (ASCT) with and without acetylsalicylic acid (ASA) as comedication.MethodsWe assessed patients who underwent ASCT at the Heidelberg University Hospital between 2011 and 2020 for bleeding events, management strategies for ASA intake during thrombocytopenia, transfusion requirements, and the occurrence of CV events.ResultsThere were 57/1,113 patients who continued ASA until at least 1 day after ASCT; thus, a continuous platelet inhibition during thrombocytopenia was assumed. Most of the patients (41/57) continued ASA until they had a platelet count of 20–50/nl. This range reflects the kinetics of thrombocytopenia and nondaily measurements of platelets during ASCT. A tendency toward a higher risk for bleeding events in the ASA group was demonstrated (1.9% (control group) vs. 5.3% (ASA), p = 0.082). The risk factors for bleeding in multivariate analysis were the duration of thrombocytopenia < 50/nl, a history of gastrointestinal bleeding, and diarrhea. The factors predicting the duration of thrombocytopenia were age >60 years, a hematopoietic stem-cell transplantation comorbidity index ≄3, and an impaired bone marrow reserve at admission. CV events occurred in three patients; none of them took ASA or had an indication for APT.ConclusionsThe intake of ASA until thrombocytopenia with a platelet count of 20–50/nl appears safe, although an elevated risk cannot be excluded. If ASA is indicated for the secondary prevention of CV events, the evaluation of risk factors for bleeding and a prolonged time of thrombocytopenia before conditioning is crucial to adapt the strategy for ASA intake during thrombocytopenia

    Validation of a proxy‐reported SARC‐F questionnaire for current and retrospective screening of sarcopenia‐related functional impairments

    Get PDF
    BACKGROUND: The strength, assistance walking, rise from a chair, climb stairs, and falls (SARC‐F) questionnaire is a well‐established instrument for screening of sarcopenia and sarcopenia‐related functional impairments. As it is based on self‐reporting, its use precludes patients who are unable to answer the questionnaire as a consequence of severe acute diseases or cognitive impairment. Therefore, we aimed to validate a proxy‐reported version of the SARC‐F for both ad‐hoc as well as retrospective screening for severe sarcopenia‐related functional impairments. METHODS: Patients aged ≄60 years completed the SARC‐F and performed the short physical performance battery (SPPB) at baseline (T1). Proxies in Cohort A gave a simultaneous assessment of the patients' functional status with the proxy‐reported SARC‐F at T1 and again, retrospectively, after 3 months (T2). Proxies in Cohort B only completed the SARC‐F retrospectively at T2. The questionnaires' performances were assessed through sensitivity/specificity analyses and receiver operating characteristic (ROC) curves. For non‐inferiority analyses, results of both the patient‐reported and proxy‐reported SARC‐F were correlated with the SPPB total score as well as the results of the chair‐rise test subcategory; the respective correlation coefficients were tested against each other. RESULTS: One hundred and four patients and 135 proxies participated. Using a SPPB score < 9 points as the reference standard, the proxy‐reported SARC‐F identified patients at high risk for sarcopenia‐related functional impairment with a sensitivity of 0.81 (ad‐hoc), 0.88 (retrospective Cohort A), and 0.87 (retrospective Cohort B) as well as a specificity of 0.89 (ad‐hoc), 0.78 (retrospective Cohort A), and 0.64 (retrospective Cohort B). Areas under the ROC curves were ≄ 0.9 for the ad‐hoc proxy‐reported SARC‐F and the retrospective proxy‐reported SARC‐F in both cohorts. The proxy‐reported SARC‐F showed a non‐inferior correlation with the SPPB compared with the patient‐reported SARC‐F for ad‐hoc (P = <0.001) as well as retrospective screening for severe sarcopenia‐related functional impairment in both Cohorts A (P = 0.007) and B (P = 0.026). CONCLUSIONS: Proxy‐reported SARC‐F is a valid instrument for both ad‐hoc as well as retrospective screening for sarcopenia‐related functional impairment and could become the standard tool for evaluating this risk in older adults with severe acute disease, for example, in patients with quickly evolving haematological conditions

    ATP-dependent chromatin remodelers - Analysis of expression patterns and impact on gene regulation

    No full text
    ATP-dependent chromatin remodelers are enzymes which use the energy from ATP hydrolysis to alter the chromatin structure. Thus, they play a key role in the transcriptional control of many important cellular processes such as proliferation,senescence and differentiation.The first part of this study focused on CHD5, a novel chromatin remodeling enzyme. To gain further insight into its expression profile and biological function, polyclonal peptide antisera were, together with a commercially available antiserum, successfully established for use in western blot, immunoprecipitation and immunofluorescence staining. ATP-dependent chromatin remodelers are expressed by very different patterns ranging from ubiquitous expression to an expression restricted to specific cell populations. So far, CHD5 expression was thought to be restricted to neural-related tissues. Here, it was shown for the first time that CHD5 expression is not restricted to neural tissues but additionally expressed in rodent testes. Furthermore, several cell lines were tested for CHD5 expression on transcript and protein level. CHD5 expression was not detected in any of the tested neuroblastoma and glioblastoma cell lines. In neuroblastoma cell lines this was expected due to the suggested function as tumor suppressor. Furthermore, a primary astrocyte culture was established. No CHD5 could be detected in protein lysates from astrocytes but was found in those from murine neural stem cells. This suggests that CHD5 expression in brain is restricted to neural stem cells and probably also to neurons. In the second part of this thesis, the impact of the chromatin remodelers CHD4 and BRG1 on a TNFα-induced inflammatory response was investigated. BRG1 and CHD4 expression was disrupted by a siRNA-mediated knockdown in HEK293 cells. After stimulations with TNFα for one to four hours, gene induction of typical inflammatory NF-ÎșB target genes was determined by RT-qPCR. BRG1 and CHD4 were both required for the efficient induction of all tested target genes exclusively after one hour but not after four hours of TNFα treatment. Expression of the housekeeping gene ß-actin was unaffected. Surprisingly, although CHD4 is mainly known to be involved in transcriptional repression, a requirement for CHD4 in active transcription during this inflammatory response was revealed. To gain further insight into the mechanism of involvement, co-immunoprecipitations of the NF-ÎșB subunit p65 with BRG1 and CHD4,respectively, were performed upon TNFα stimulation. No robust interactions between these proteins could be observed. Furthermore, ChIP experiments with the NF-ÎșB subunit p50, histone H3 and CHD4 were carried out on the model target gene CXCL2. p50 was recruited to the promoter of CXCL2 rapidly after TNFα was added. Histone H3 binding to the promoter and the open reading frame of the gene strongly decreased within the first hour of TNFα stimulation, indicating that chromatin remodeling took place during the early period of gene induction. Recruitment of CHD4 was nonconclusive. Thus, the mechanism of how BRG1 and CHD4 act during TNFα response needs to be investigated further. In summary, a major influence of the chromatin remodelers BRG1 and CHD4 on the TNFα-induced gene activation during its early phase in HEK293 cells was demonstrated

    C. Literaturwissenschaft.

    No full text
    corecore